Alessio Branchini Shares His Latest Work on Albumin-Fused Factor IX Variants and Thanks The Whole Team
Alessio Branchini, Associate Professor of Molecular Biology at University of Ferrara, shared on LinkedIn:
”Very proud to announce that our paper is published!
Great and hard, but exciting, work on the characterization and biodistribution of engineered albumin-fused factor IX variants with tailored biinding to extravascular collagen.
Wonderful collaborations involving our group at the University of Ferrara, the team at the University of Oslo and the San Raffaele Hospital.
From the University of Ferrara side, excellent work by Maria Francesca Testa, Rebecca Tarantino and Mascia Benedusi.
Very thankful to Jan Terje Andersen, Kristin Hovden Aaen and Jeannette Nilsen (University of Oslo for the wonderful and ongoing collaboration (10 years!), to Alessio Cantore and Cesare Canepari (Ospedale San Raffaele) for their extremely valuable contribution, as well as to all collaborators.
Together we made this story possible.
Of course, a particular thank you to my (and our) mentors Francesco Bernardi and Mirko Pinotti at the University of Ferrara.
Last but not least, I am really grateful to the Access to Insight Basic Research Grant program by Novo Nordisk.
Press releases on Eurekalert and on the news site of University of Ferrara.”
Read the full article in Nature Communications.
Article: Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties
Authors: Kristin Hovden Aaen, Maria Francesca Testa, Jeannette Nilsen, Rebecca Tarantino, Cesare Canepari, Mascia Benedusi, Sopisa Benjakul, Mari Nyquist-Andersen, Marie Leangen Herigstad, Alessio Cantore, Giuseppe Valacchi, Inger Sandlie, Francesco Bernardi, Mirko Pinotti, Alessio Branchini, Jan Terje Andersen
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH
-
Feb 23, 2026, 17:59Wolfgang Miesbach: Real-World Evidence of Emicizumab on Joint Outcomes in Hemophilia A
-
Feb 23, 2026, 17:56Shiny K Kajal: The Transfusion Reaction We Often Miss
-
Feb 23, 2026, 17:53Radheshyam Meher: Contributing to the Transfusion Evidence Round-Up for International Childhood Cancer Day 2026
-
Feb 23, 2026, 17:46Mahesan Subramaniam: The Physiological Impact of Anger on Immunity
-
Feb 23, 2026, 17:42Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch